文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

2018-21年突尼斯抗生素耐药性调查(SOAR):基于CLSI、EUCAST和PK/PD折点的数据

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该研究测定了2018-21年突尼斯两所医院社区获得性呼吸道感染分离的肺炎链球菌(n=58)和流感嗜血杆菌(n=71)的MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点解读敏感性。结果显示肺炎链球菌对多数药物敏感率有限,仅头孢曲松等少数药物保持较高活性;流感嗜血杆菌敏感率较高,但仅头孢曲松在CLSI和EUCAST下均达100%敏感。

要点

  • 肺炎链球菌对青霉素的敏感率因折点而异:CLSI口服/EUCAST低剂量为22.4%,EUCAST高剂量/CLSI静脉为89.7%。
  • 肺炎链球菌对大环内酯类、四环素类和复方磺胺甲噁唑的敏感率仅41.4%-65.5%。
  • 流感嗜血杆菌对头孢曲松100%敏感,但对氨苄西林(CLSI 60.6%)和复方磺胺甲噁唑(CLSI 77.5%)敏感率较低。

核心结论

  • 突尼斯社区获得性呼吸道感染肺炎链球菌中敏感率≥90%的治疗选择很少。
  • 流感嗜血杆菌分离株敏感率较高,但仅头孢曲松在CLSI和EUCAST下对两种菌均达100%覆盖。
  • 持续监测对指导经验性治疗很重要。

研究设计与样本

  • 研究纳入2018-21年突尼斯两所医院社区获得性呼吸道感染分离的肺炎链球菌(n=58)和流感嗜血杆菌(n=71)。
  • 采用CLSI肉汤微量稀释法测定MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点解读敏感性。

主要发现

  • 肺炎链球菌对头孢曲松、左氧氟沙星和莫西沙星在CLSI或PK/PD折点下敏感率≥91.4%,对阿莫西林、阿莫西林/克拉维酸和头孢噻肟为82.8%-87.9%。
  • 肺炎链球菌对四环素类、大环内酯类和复方磺胺甲噁唑敏感率为41.4%-65.5%,对头孢地尼和第二代头孢菌素敏感率仅24.1%-51.7%。
  • EUCAST标准下仅高剂量头孢曲松、莫西沙星和高剂量左氧氟沙星对肺炎链球菌敏感率≥96.6%。
  • 流感嗜血杆菌中66.2%为β-内酰胺酶阴性,其中EUCAST和CLSI标准下分别有6株和2株对氨苄西林耐药。
  • 流感嗜血杆菌对多数抗生素CLSI敏感率≥91.5%,但氨苄西林为60.6%、复方磺胺甲噁唑为77.5%;EUCAST下多数药物敏感率低于CLSI,但高剂量阿莫西林/克拉维酸EUCAST为93.0%、高剂量PK/PD为97.2%。

关键数值与推荐

  • 肺炎链球菌对青霉素敏感率:CLSI口服/EUCAST低剂量折点22.4%,EUCAST高剂量/CLSI静脉折点89.7%。
  • 肺炎链球菌对头孢曲松、左氧氟沙星和莫西沙星CLSI或PK/PD敏感率≥91.4%。
  • 肺炎链球菌对四环素类、大环内酯类和复方磺胺甲噁唑敏感率41.4%-65.5%。
  • 流感嗜血杆菌对头孢曲松CLSI和EUCAST敏感率均为100%。
  • 流感嗜血杆菌对氨苄西林CLSI敏感率60.6%,对复方磺胺甲噁唑CLSI敏感率77.5%。

临床怎么用

  • 经验性治疗突尼斯社区获得性呼吸道感染时,应考虑肺炎链球菌对多数口服药物敏感率有限。
  • 头孢曲松对肺炎链球菌和流感嗜血杆菌均保持高敏感率,可作为经验性治疗的重要选择。
  • 应依据当地药敏监测数据选择药物,并注意不同折点标准对敏感率解读的差异。

局限性

  • 研究仅纳入突尼斯两所医院的分离株,样本量有限(肺炎链球菌n=58,流感嗜血杆菌n=71)。
  • 研究为横断面调查,未报告患者临床结局或治疗失败数据。
  • 敏感性解读依赖折点标准,不同标准间结果差异较大,可能影响临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the antibiotic susceptibility of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2018-21 from two hospitals in Tunisia. METHODS: MICs were determined by CLSI broth microdilution, and susceptibility data were interpreted using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae (n = 58) and H. influenzae (n = 71) isolates were collected; 22.4% of pneumococci were penicillin-susceptible by CLSI oral/EUCAST low-dose breakpoints, but 89.7% were susceptible by EUCAST high-dose/CLSI intravenous administration breakpoints. Susceptibility to ceftriaxone, levofloxacin and moxifloxacin was ≥91.4% by CLSI or PK/PD breakpoints which reduced to 82.8%-87.9% for amoxicillin, amoxicillin/clavulanic acid and cefotaxime. Tetracyclines, macrolides and trimethoprim/sulfamethoxazole were 41.4%-65.5% susceptible, with cefdinir and second-generation cephalosporins less active (24.1%-51.7% susceptible). EUCAST indicated ≥96.6% susceptibility only to high-dose ceftriaxone, moxifloxacin and high-dose levofloxacin. Most H. influenzae (66.2%) were β-lactamase negative, of which six and two isolates were ampicillin-resistant following EUCAST and CLSI criteria, respectively. Antibiotic susceptibility was ≥91.5% (CLSI) except for ampicillin (60.6%) and trimethoprim/sulfamethoxazole (77.5%). Susceptibility by EUCAST was lower than CLSI for most other antimicrobials, except for high dose amoxicillin/clavulanic acid (93.0% by EUCAST, 97.2% high dose PK/PD). Both CLSI and EUCAST showed 100% susceptibility to ceftriaxone. CONCLUSIONS: Few therapeutic options with ≥90% susceptibility for the treatment of S. pneumoniae from CA-RTIs in Tunisia remain. Although H. influenzae isolates displayed higher susceptibility, only ceftriaxone provides 100% coverage for both species following CLSI and EUCAST guidelines. Continued surveillance is important for guiding empiric therapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Slim L, Hammami A, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277340. doi:10.1093/jac/dkaf286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。